Is It Too Late to Buy Moderna Stock?
Moderna (NASDAQ: MRNA) took center stage last spring when it became the first to bring an investigational coronavirus vaccine into human trials. Nine months later, it brought that vaccine to the public after earning an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The stock climbed more than 430% last year -- rewarding short-term and long-term investors along the way. And the trend continues. Moderna's shares are up 60% so far in 2021.
Now the question is: Can new investors in the stock can still benefit? Or is it too late to get in on this coronavirus vaccine success story? The answer depends on the company's future revenue prospects and position in the vaccine market. And it also depends on a potential investor's investment horizon.
Image source: Getty Images.
Source Fool.com
